Brass, E. P. (2013). Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? American Diabetes Association.
Citação norma ChicagoBrass, Eric P. Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in Sync? American Diabetes Association, 2013.
MLA引文Brass, Eric P. Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in Sync? American Diabetes Association, 2013.
警告：這些引文格式不一定是100％准確.